Abstract 568
Background
The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general population. Tamoxifen, chemotherapy and breast irradiation are associated with an increased risk of SPM. The aim of this study was to investigate the clinicopathological characteristics of the non BC SPM in p with primary diagnostic of BC.
Methods
We conducted a retrospective study in a cohort of 2,111 women with BC diagnosed between 1975 and 2014 in a regional cancer institute in Spain. We evaluated the incidence and pattern of SPM per Warren and Gates criteria, and the impact of breast cancer treatment on SPM.
Results
57p (2.7%) of the cohort developed a SPM, 13 of them (23%) had synchronous tumors and 44p (77%) had metachronous tumors. 10p (18%) developed a third primary malignancy and 1p (1.7%) developed a fourth primary malignancy. The most frequent SPM were hematological malignancies (HM) (11p, 19%), followed by endometrial (7p, 12.3%), gastric (7p, 12.3%), lung (6p, 10.5%), parotid tumors (6p, 10.5%) and melanoma (6p, 10.5%). The mean latency period for SPM was 62.7 months. HM were developed in 0.52% of the cohort of 2,111p. Myeloid neoplasms were diagnosed in 6p (0.28%). Among them, 1p developed chronic myeloid leukemia and 5p developed myelodysplastic syndromes (MDS), including refractory anemia with excess blasts-2 (2p) and 5q minus syndrome (2p). Lymphoid neoplasms were diagnosed in 5p (0.24%). The incidence of HM was similar in both anthracycline-treated and not treated p (0.48% and 0.58%, respectively). The incidence of HM in p treated with radiotherapy was higher than in p who did not receive radiotherapy (0.65% vs 0.19%).
Conclusions
HM are the most frequent non BC SPM in p treated from BC; frequently they are therapy related neoplasms. Deescalating chemotherapy and radiotherapy in BC and finding genetic markers of early malignancy detection are mandatory.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5658 - Detection of 5-hydroxymethylcytosine in Circulating-Free DNA for Early Diagnosis of Colorectal Cancer
Presenter: Tianyu Liu
Session: Poster Display session 2
Resources:
Abstract
5779 - Detection of 5-hydroxymethylcytosine in Circulating-Free DNA for Prediction of The Efficacy of Conversion Therapy for Colorectal Cancer Liver Metastases
Presenter: Wenju Chang
Session: Poster Display session 2
Resources:
Abstract
4672 - mCRC gene profiling using the Idylla platform
Presenter: Christopher Bricogne
Session: Poster Display session 2
Resources:
Abstract
3393 - PIK3CA mutation in metastatic colorectal cancer (mCRC): association with clinico-pathological features and outcome
Presenter: Valentina Fanotto
Session: Poster Display session 2
Resources:
Abstract
1317 - Patient-Derived Xenografts (PDX) Identifies JMJD6 Inhibitor as an Effective Therapeutic Medicine in Colorectal Cancer.
Presenter: Feng Ye
Session: Poster Display session 2
Resources:
Abstract
1228 - DACH1 induced stemness of intestinal organoids by directly suppressing BMP signaling and contributes to intestinal tumorigenesis
Presenter: Xiang Hu
Session: Poster Display session 2
Resources:
Abstract
1147 - miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions
Presenter: Hsiang-lin Tsai
Session: Poster Display session 2
Resources:
Abstract
1158 - Long noncoding RNA CASC21 promotes cell proliferation and metastasis in colon cancer.
Presenter: Qun Zhang
Session: Poster Display session 2
Resources:
Abstract
1259 - Prognostic and Predictive Impact On FMS-like Tyrosine Kinase 3 (FLT3) Amplification In Patients With Metastatic Colorectal Cancer
Presenter: Hiroko Hasegawa
Session: Poster Display session 2
Resources:
Abstract
1452 - RBP-Jκ in colon cancer cells facilitates tumor associated macrophages (TAMs)-induced cell metastasis by secreting CXCL11
Presenter: Meng jie Liu
Session: Poster Display session 2
Resources:
Abstract